Diabetes and Fatty Liver.

Authors :: Stefan N
Roden M
Source :: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association [Exp Clin Endocrinol Diabetes] 2022 Sep; Vol. 130 (S 01), pp. S113-S116. Date of Electronic Publication: 2022 Apr 01.
Publication Year :: 2022
Abstract: Competing Interests: N. S. has participated in Scientific Advisory Boards of Allergan, Intercept Pharma, MSD, Pfizer, Novo Nordisk, Gilead, Genkyotex, Astra-Zeneca, Boehringer Ingelheim, Sanofi, and clinical trials of AstraZeneca, Boehringer Ingelheim, Sanofi, DSM Nutritional Products and Roche Diagnostics. M. R. has participated on Scientific Advisory Boards of BMS, Boehringer Ingelheim Pharma, Eli Lilly, Fishawack Group, Gilead Sci., Novo Nordisk, Poxel S.A. Sociéte, Prosciento Inc., Sanofi, Servier Lab., Target Pharmasolutions, Terra Firma and in clinical trials of Astra Zeneca, Boehringer Ingelheim, Nutricia/Danone and Novartis.

Subjects :: Humans
Diabetes Mellitus, Type 2 therapy
Fatty Liver diagnosis
Fatty Liver therapy
Insulin Resistance
Non-alcoholic Fatty Liver Disease therapy

Language :: English
ISSN :: 1439-3646
Volume :: 130
Issue :: S 01
Database :: MEDLINE
Journal :: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
Publication Type :: Academic Journal
Accession number :: 35373310
Full Text :: https://doi.org/10.1055/a-1624-3541